On March 25, the leader of central nervous system drugs Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) ( Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) ) released the performance report for 2021. During the reporting period, the company achieved an operating revenue of 3.936 billion yuan, an increase of 17.09% over the same period of last year; The net profit attributable to shareholders of listed companies was 798 million yuan, an increase of 9.46% over the same period last year.
Under the background of repeated outbreaks of centralized procurement and covid-19 pneumonia, Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) continued to strengthen the promotion of non centralized procurement and newly listed products, so that the company’s operating income and net profit maintained a relatively stable growth. In addition, Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) continued to increase the investment in drug R & D, and implemented the development strategy of separating innovation from imitation and paying equal attention to innovation and imitation. The R & D cost increased by 50.89% over the same period.
projects under research more than 70 items
Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) formerly known as Xuzhou No. 3 pharmaceutical factory, after a series of restructuring, reorganization and integration, the company has become a leading enterprise in specialized drugs for the central nervous system. At the same time, the company is also the only pharmaceutical enterprise in China that focuses on the R & D and production of drugs for the central nervous system. Over the past three decades, the company’s product echelon has become increasingly rich. In the subdivided fields of central nervous drug industry, there are heavy product layouts in spirit, nerve, anesthesia and analgesia.
In 2021, Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) reduced its holdings, separated innovation and imitation, and paid equal attention to innovation and imitation. It continuously increased its R & D investment in innovative drugs, high policy barriers and high-tech generic drugs, and the proportion of R & D investment continued to increase.
At present, Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) is researching more than 70 scientific research projects, with 402 million yuan invested in scientific research, an increase of 50.89% over the previous year, and remarkable R & D achievements have been achieved. The company’s penehyclidine hydrochloride injection, sufentanil citrate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric coated capsule and other heavy drugs have been approved successively; 10 generic varieties passed the consistency evaluation. Other key innovative drug projects under research include oxalidine fumarate (trv-130) injection, nh600001 emulsion injection, protollin nasal spray, cy150112 tablets, nh102 hydrochloride tablets, nhl35700, etc; Key projects of improved new drugs include nh510, ketamine hydrochloride (R) nasal spray, ketamine hydrochloride (R) injection, etc; The key projects of generic drugs include dizocine injection, etomidate medium and long chain fat emulsion injection, lorazepam injection, clonazepam injection, aripiprazole long-acting injection and a series of products. With the approval and marketing of these products, the company will further consolidate its leading position in China in the field of central nervous drugs.
16 innovative drugs ready to go
The field of nervous system drugs is the main direction of Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) research and development, covering all central nervous system drugs. It is the enterprise with the most complete and most varieties of drugs in the central nervous system field in China.
The reporter of securities times · e company learned that at present, the company has more than 20 new drug research projects, including 4 phase I clinical research projects; Other projects are in the stage of applying for preclinical systematic pharmacy and toxicology research or preclinical candidate drug research.
( Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) new drug research and development project and schedule)
It is worth noting that at the beginning of this year, Trevena company of the United States exclusively authorized Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) in Greater China to develop and commercialize a new opioid postoperative analgesic, oxalidine fumarate injection (hereinafter referred to as “trv130”), which was accepted by the State Drug Administration, The drug is mainly used to treat moderate to severe acute pain in adult patients who need intravenous opioids.
Intravenous opioids are an important treatment option for millions of hospital patients. It is estimated that more than 45 million patients receive such painkillers every year. Intravenous opioids are considered an important part of the patient’s pain management program, especially for surgery where severe, long-term or deep / visceral pain is expected. Clinical studies have shown that trv130 reaches the peak pain faster than morphine, and the risk of gastrointestinal dysfunction and respiratory depression caused by this product at the equivalent analgesic dose is less than morphine. These advantages may help Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) stir up the postoperative analgesia market in the future.
According to data, oliceridine has about $1.5 billion in analgesic market opportunities in the United States. At present, the total market scale of general and local narcotic drugs in China is about 5 billion yuan, and the market scale of narcotic drugs is about 2 billion yuan.
At present, the per capita consumption of narcotic drugs in China is 1 / 10 of that in developed countries, and the consumption of medical morphine accounts for 2% of the world. In the past five years, the compound growth rate of hemp essence drugs in China has reached 28.5%, higher than the average growth rate of the pharmaceutical industry, highlighting the huge unmet clinical demand. The market for morphine addiction and adverse reactions is shrinking year by year. Trv130 is likely to replace morphine as the main analgesic drug in the future.
